IO Biotech announced three poster presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting, SITC, being held in San Diego, California from November 1-5, 2023. “The data presented provide clear evidence that our immune modulating vaccines, developed based on our T-win technology platform, impact several immune escape mechanisms as elegantly exemplified in abstract #1468,” said Mai-Britt Zocca, PhD, President and Chief Executive Officer of IO Biotech. “The data in this poster demonstrate enhanced in vivo anti-tumor effect when IDO and PD-L1 vaccines are co-administered in these models, further supporting the clinical observations regarding our lead investigational therapeutic vaccine candidate, IO102-IO103, which targets IDO and PD-L1. Data from clinical trials of IO102-IO103 administered with a PD-1 inhibitor demonstrated enhanced anti-tumor activity in multiple tumor types, including metastatic melanoma, non-small cell lung cancer and squamous cell cancer of the head and neck.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IOBT:
- IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress
- IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- IO Biotech initiated with an Overweight at Piper Sandler
- IO Biotech announces data related to IO102-IO103 in combination with KEYTRUDA